Cash Flow Statement

Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Xilio Therapeutics (XLO) Depreciation and Depletion (2024 - 2025)

Xilio Therapeutics (XLO) has disclosed Depreciation and Depletion for 2 consecutive years, with $300000.0 as the latest value for Q4 2025.

Quarterly Depreciation and Depletion fell 25.0% to $300000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Dec 2025, down 6.25% year-over-year, with the annual reading at $1.5 million for FY2025, 6.25% down from the prior year.
Depreciation and Depletion hit $300000.0 in Q4 2025 for Xilio Therapeutics, roughly flat from $300000.0 in the prior quarter.
In the past five years, Depreciation and Depletion ranged from a high of $500000.0 in Q1 2025 to a low of $300000.0 in Q3 2025.